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SurvivorshipThe population of cancer survivors has grown steadily over the past several decades.
Surviving cancer, however, is not synonymous with a life free of problems related to the
disease and its treatment. In this paper we provide a brief overview of selected physical
and psychosocial health problems prevalent among cancer survivors, namely pain, fatigue,
psychological distress and work participation. We also address issues surrounding
self-management and e-Health interventions for cancer survivors, and programmes to
encourage survivors to adopt healthier lifestyles. Finally, we discuss approaches to
assessing health-related quality of life in cancer survivors, and the use of cancer registries
in conducting psychosocial survivorship research. We highlight research and practice
priorities in each of these areas. While the priorities vary per topic, common themes that
emerged included: (1) Symptoms should not be viewed in isolation, but rather as part of a
cluster of interrelated symptoms. This has implications for both understanding thesmanlaan
E J C S U P P L E M E N T S 1 2 ( 2 0 1 4 ) 5 4 –6 4 55aetiology of symptoms and for their treatment; (2) Psychosocial interventions need to be
evidence-based, and where possible should be tailored to the needs of the individual cancer
survivor. Relatively low cost interventions with self-management and e-Health elements
may be appropriate for the majority of survivors, with resource intensive interventions
being reserved for those most in need; (3) More effort should be devoted to disseminating
and implementing interventions in practice, and to evaluating their cost-effectiveness; and
(4) Greater attention should be paid to the needs of vulnerable and high-risk populations of
survivors, including the socioeconomically disadvantaged and the elderly.
 2014 European Organisation for Research and Treatment of Cancer. Published by Elsevier
Limited. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/3.0/).1. Introduction
More than half of European patients diagnosed with cancer
survive 5 years or longer after their primary diagnosis [1].
A disease-free status, however, is not synonymous with a
life free of physical and psychosocial health problems
related to the cancer and its treatment. In this paper we
provide a brief overview of selected psychosocial issues in
cancer survivorship. Specifically, we focus on pain, fatigue,
psychological distress and work participation. We also
address issues surrounding self-management and e-Health
interventions for cancer survivors, and programmes to
encourage survivors to adopt healthier lifestyles. Finally,
we examine approaches to assessing health-related quality
of life in cancer survivors, and the use of cancer registries
in conducting psychosocial survivorship research. Our intent
is not to provide a comprehensive review of these topics, but
rather to briefly summarise the current state of affairs and,
more importantly, to highlight what we believe are some of
the priorities for future research and clinical care develop-
ment initiatives.
2. Pain and pain management
Chronic pain is one of the most distressing and disabling
symptoms experienced by cancer patients and survivors.
Knowledge of pain and its effects on cancer survivors is still
limited due to the small number of studies, and thus it is
often left unrecognised and untreated [2].
Pain is not only caused by tissue damage produced by the
cancer itself but can also be caused by treatment-related toxic
or traumatic damage to peripheral and central neural struc-
tures, resulting in long-lasting or even late onset neuropathy.
Pain may persist after treatment or may emerge several
months or even years after treatment has been completed.
This is described as post-cancer pain syndrome.
Pain rates of 30–50% have been reported in cancer survi-
vors, varying as a function of diagnosis, stage, disease status,
comorbid conditions, initial pain management, patient char-
acteristics (e.g. sex, cultural background) and measures used
to assess pain. Importantly, pain is also reported in disease-
free cancer survivors. An analysis of the 2002 National Health
Interview Survey in over 30,000 persons found that the preva-
lence of pain in cancer survivors was much higher (34%) than
in controls without a history of cancer (18%) [3]. The highestprevalence rates were observed in post-thoracotomy (up to
80%), post-amputation/phantom limb (50% to 80%), post-neck
dissection (52%) and breast cancer (63%) patients [4].
Post-cancer pain syndromes should be viewed as part of a
cluster of symptoms, including fatigue, anxiety, depression
and sleep disturbance. All of these symptoms may be caused,
at least in part, by a common, underlying biological mecha-
nism. Combined, these symptoms have a negative impact
on survivors’ physical and psychosocial functioning [5].
Chronic pain is a persistent stressor that indirectly affects
the feedback loop of the hypothalamic–pituitary–adrenal
(HPA) axis through involvement of brain regions in the limbic
system. The HPA axis is also activated in response to psycho-
logical stressors such as depression and anxiety [6]. Emo-
tional distress, depression, anxiety and fear may contribute
significantly to the resulting pain experience [7].
Even when the 3-step WHO pain ladder is employed, com-
plete relief from chronic cancer pain may be an unrealistic
expectation in somepatients [8]. Opioid therapy is auseful tool,
but in the survivorship setting its use is often discouraged due
to long-term side effects, including the development of opiate-
inducedhyperalgesia, aswell as the riskof abuse andaddiction
[9]. Non-opioid medication options include antidepressants,
antiepileptic drugs and topical agents, in addition to non-ste-
roidal anti-inflammatory agents and acetaminophen [10].
Intrathecal therapies with non-opioid alternatives, such as
ziconotide or other drugs, should also be considered for the
management of chronic pain, particularly if it is neuropathic
[9]. Gene therapy represents a potentially useful, new
approach. However, this requires careful selection of a thera-
peutic gene that properly modulates the nociceptive cascade
without causing additional complications for the patient [11].
In selected patients, interventional modalities may be consid-
ered, including nerve blocks, trigger point injections, spinal
cord stimulators or implanted intrathecal pumps [10].
An equally if not more useful approach may be to encour-
age survivors to actively participate in the plan of care for
their pain management, with an emphasis on self-activation
and non-pharmacologic therapies, and to help them focus on
certain outcomes such as improved functional capacities,
restorative sleep, social activities, mood and coping, which
may help to reduce pain to a tolerable level [5,10].
Our knowledge and understanding of chronic pain in can-
cer survivors can be enhanced by: (1) investigations of symp-
tom clusters and the total symptom burden experienced by
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healthy individuals and those with other chronic diseases; (3)
comparing the pain experience of short- versus long-term
survivors; (4) studying a wide range of survivor populations,
as much of the current evidence is based on breast cancer
survivors; (5) studies of the mechanisms involved in the tran-
sition from acute pain to chronic pain syndromes; and (5)
continuing studies of both pharmacologic and behavioural
managements of chronic pain.3. Cancer-related fatigue
We know that the majority of patients experience cancer-
related fatigue (CRF) during cancer treatment, and that it
can have a profound impact on both physical and psychoso-
cial functioning [12]. What is less clear is why some patients
recover quickly from CRF while for others it develops into a
chronic state. There is a need to understand the mediators
of CRF including pain, mood state and inflammatory pro-
cesses, in order to design suitable interventions.
Early screening and detection is an important first step, and
may be initiated even before the cancer treatment begins.
Screening for CRF canbe donewith stand alonequestionnaires
[13], but can also be embedded in a broader health status or
quality of life assessments [14,15], and may be combined with
performance indicators of functioning. Potentially, screening
could also include storing serum for genetic polymorphisms
or inflammatory marker measurement, as there is consistent
evidence that these mediate the process of CRF [12].
There are currently many questionnaires available for
assessing CRF, although most have not been developed for
or specifically tested in the cancer survivorship setting [16].
Ideally, we should have at our disposal a very limited number
of widely accepted measures of fatigue that would allow us to
compare results across populations and studies. Such mea-
surement uniformity, or at least comparability, may be facili-
tated by current efforts underway in both the United States
and in Europe to develop fatigue measures based on item
response theory (e.g. the PROMIS initiative in the US [17];
the Computer Adaptive Testing project of the EORTC Quality
of Life Group [18]). An additional challenge is to agree upon
a definition of clinically significant levels of CRF and of its
reduction as the result of interventions [12].
We also need a comprehensive model, including both
somatic and psychosocial factors, for understanding the
multi-causal development of CRF. We know that CRF mani-
fests itself in compromised performance and functioning,
but why such problems persist and become chronic in some
patients but not in others is unclear [19]. To better understand
the development and course of CRF, we need longitudinal
studies with long-term (e.g. 5 to 10 year) follow up after com-
pletion of primary treatment. These could be freestanding,
observational studies, but we may also be able to embed
CRF assessments in new or on-going cancer clinical trials.
Although patients who participate in clinical trials may not
be representative of the larger population of cancer patients,
the clinical trial setting may offer a unique opportunity to
relate changes in CRF over time to detailed disease- and treat-
ment-related variables.Additional opportunities are available through linkage of
various data sources, including patient self-reported CRF, per-
formance indicators (e.g. step counts) and employment data.
Fatigue can be a significant factor affecting return to work,
and thus such linkages could provide us with important
insights into the economic costs of CRF.
We have a broad evidence base for the use of exercise and
psychological therapies for treating CRF, but the effect sizes of
these interventions tend to be small [20,21]. Most of the evi-
dence is based on studies of patients under treatment, using
resource intensive interventions [22,23]. Thuswe need studies
of practical interventions carried out during treatment with
long-term follow-up, and interventions initiated after primary
treatment has ended [23]. This will provide us with evidence
regarding the value of early interventions to reduce peak CRF
on treatment leads and to minimise chronic CRF in survivors.
While low cost, psycho-educational and self-management
interventions for CRF could be developed and made available
to large populations of cancer patients, more intensive forms
of intervention should be reserved for those who need it the
most. Thus, again, appropriate screening is necessary to tar-
get that subset of cancer patients and survivors who are suf-
fering from or are most likely to develop chronic CRF [12]. To
date, there have been only a few studies showing that early
supportive strategies during treatment may prevent CRF as
a late effect [24]. Therefore research on evaluation of early
rehabilitation strategies for prevention of CRF in cancer survi-
vors is also an important research task.
Understanding CRF is important for evidence-based
resource allocation and for making the case for additional ser-
vices. This could include subsidised gym membership or an
exercise prescription initiated during treatment and moni-
tored through the survivorship period [25]. It is also important
to engage primary care physicians so that there is continuity
of care from the active treatment phase through long-term
survivorship. This could be incorporated into an individual
survivorship care plan.4. Psychosocial and psychological distress:
assessment and treatment interventions
Across all diagnoses, cancer patients are at significantly
increased risk for psychological symptoms [26]. Distress is a
broad construct including a wide continuum of emotions
related to, among others, symptoms of depression, anxiety
and adjustment disorder [27]. Overall, distress in cancer
patients is often reported to be above 30% [28]. The prevalence
of depressive symptoms varies between 10 and 25% [29], and
a significantly increased risk for hospital admission for
depression has been reported [30]. Anxiety symptoms vary
between 10 and 30% [31]. High levels of comorbid symptoms
of anxiety and depression have been reported and genetic risk
factors for both have been shown to correlate strongly [32].
However, symptoms of anxiety and depression may also
occur independently and progress quite differently after a
cancer diagnosis. This process remains almost unexplored
in cancer survivors.
A large number of randomised clinical trials (RCT’s) have
investigated whether psychological symptoms in cancer
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interventions. Multiple reviews and meta-analyses have
attempted to evaluate the evidence, but despite a somewhat
overlapping pool of studies being evaluated, the conclusions
are surprisingly divergent. Some reviews conclude that psy-
chological interventions have a significant, positive effect
[33], while others report a lack of convincing evidence on
the efficacy of psychological interventions [34]. The observed
discrepancies between these reviews may reflect varying
quality of reporting in the various RCT’s, which makes it chal-
lenging to compare results across studies [35].
It has been argued that the most promising and effective
interventions are those targeted at high-risk cancer groups
[36]. This suggests that screening for psychological distress,
with appropriate referral to interventions among those at high
risk, will increase the effectiveness of interventions. However,
only a few RCTs have investigated the effect of screening-
based interventions on psychological symptoms. Again, the
conclusions drawn have been inconsistent, reflecting signifi-
cant variability in the quality of reporting in the trials [37–39].
To move forward, the methodological quality of psycholog-
ical intervention studies needs to be improved substantially.
This includes carrying out pilot and feasibility testing prior
to starting an RCT, generating protocol-based interventions
and raising the standards of reporting of RCT’s in this area
of research. This will facilitate the interpretation of results
across studies, and should result in more consistent conclu-
sions being drawn from systematic reviews. Additional atten-
tion needs to be devoted to implementation of those
programmes demonstrated to be effective.
Psychological symptoms experienced by cancer patients
are not static, but rather are likely to change over time [40].
To improve the quality and efficacy of our interventions, we
need to better understand the natural history of distress,
depression and anxiety from pre-cancer diagnosis through
to long term survivorship, the risk and protective factors
involved, and the recovery process, with and without support.
Such trajectories have been the subject of study in a few
investigations, and have aided in identifying especially vul-
nerable subgroups of cancer patients and survivors [40–44].
There is accumulating evidence that psychological distress
does not exist independently of social circumstances [45].
This suggests the need for conceptual and treatment models
that place greater emphasis on the interplay between psycho-
logical and social factors.
Finally, given increasing health care costs and reduced
budgets, we need to ‘think smart and do smart’ by tailoring
and targeting our interventions to those at highest risk of
developing psychological problems that are not self-limiting
and may become chronic. Timely treatment of distress will
not only benefit the psychological well-being of cancer survi-
vors, but may also enhance compliance with maintenance
adjuvant therapies, and could possibly play a role in survival
as well [46].5. Self-management and eHealth
Supportive care for cancer survivors is multidisciplinary and
aims to improve quality of life, including physical andpsychosocial functionings and healthy lifestyle [47]. Although
there is evidence that supportive care targeting cancer survi-
vors and their families can be effective [48–50], referral rates
are low and many survivors have unmet needs [51].
In recent years, several new models of organising support-
ive care have emerged. The Chronic Care Model includes the
health delivery system (promoting care in an effective, effi-
cient manner), the clinical information system (facilitating
efficient and effective care), decision support (consistent with
scientific evidence and patient preferences), self-manage-
ment support (empowering patients to manage their health
and health care) and the community (mobilising community
resources to meet patients’ needs) [52].
Disease management refers to a system of coordinated,
comprehensive care along the continuum of cancer and
across health care delivery systems, with a special focus on
self-management [53]. Stepped care also has the potential to
improve the efficiency of supportive care. Usually stepped
care includes the following care pathway: watchful waiting,
(guided) self-help, brief face-to-face therapies or counselling
and specialised interventions [54]. Cancer survivors play an
active role in these modern care models, and eHealth is seen
as a means of facilitating innovate supportive care.
Self-management is defined as ‘those tasks that individu-
als undertake to deal with the medical, role and emotional
management of their health condition(s)’ [55]. Self-manage-
ment strategies are intended to empower cancer survivors
and increase their self-efficacy. Empowered patients are those
who are successful in managing their condition, collaborating
with their health care providers and accessing appropriate
and high-quality (supportive) care [55].
eHealth (or mHealth (mobile Health)) involves using infor-
mation and communication technology (including mobile
devices) to improve health care [56]. Beneficial effects of
eHealth in cancer care have been reported for, among other
outcomes, health literacy, decision making, health care par-
ticipation [56], psychological well-being [57], physical activity
levels [58] and quality of life [56].
There is a growing interest in self-management and
eHealth among cancer survivors, health care providers, insur-
ers and policy-makers as a means of facilitating and improv-
ing supportive care. However, despite high expectations,
many cancer survivors and care providers have concerns
regarding confidentiality and security, inappropriate use of
(unguided) self-management and eHealth tools, cost-effec-
tiveness and lack of reimbursement. In many cases, eHealth
applications are designed by web-technologists who have lit-
tle knowledge of the key stakeholders, which hinders sustain-
able adoption of eHealth tools in supportive care.
The development of self-management and eHealth tools
should be based on relevant theoretical and applied models,
such as Bandura’s social learning theory, theory of planned
behaviour, cognitive behavioural therapy and problem solving
therapy [55–57]. In addition, (e)health literacy skills need to be
taken into account to ensure usability of these tools. With the
recent explosion of self-management and eHealth tools,
knowing which are cost-effective, for whom, and at what
point in the cancer trajectory is a challenge for both cancer
survivors and health care providers. In order to embed such
tools in routine supportive care, it is also important to take
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account, and to identify barriers, both real and perceived.
Recently, a new framework for the development of eHealth
technologies has been proposed that is based on a participa-
tory development approach, persuasive design techniques
and business modelling [59]. This framework serves as an evi-
dence-based roadmap for the development and implementa-
tion of new eHealth technologies in health care and may also
be used for developing self-management interventions.
There is a clear need for more research on the develop-
ment, cost-effectiveness and implementation of self-man-
agement and eHealth tools targeting cancer survivors. Three
top research priorities are: (1) obtaining insight into the atti-
tude towards and the barriers to and facilitators of self-man-
agement and eHealth tools; (2) development of self-
management and eHealth tools targeting quality of life issues
important to cancer survivors, based on evidence-based mod-
els and applied theories; and (3) evaluation of the cost-effec-
tiveness and implementation strategies for self-management
and eHealth tools embedded in supportive care models.
6. Health behaviour and lifestyle
interventions in cancer survivors
Cancer survivors are at risk for recurrence, second cancers
and comorbid conditions [60]. In particular, those who are
overweight, obese and/or inactive are at increased risk for
cancer-related mortality [61,62]. A growing body of evidence
indicates that a healthy lifestyle is associated with a reduced
risk of morbidity and mortality after cancer. Recent system-
atic reviews and meta-analyses conclude that behavioural
interventions are safe, efficacious and feasible when imple-
mented in controlled clinical settings. Specifically, research
shows that physical activity interventions are safe [63] for
cancer survivors and improve physical function, strength,
cardiorespiratory fitness, fatigue, mental health (e.g. depres-
sion) and health-related quality of life (HRQOL) [63–65]. Die-
tary interventions have been shown to improve diet quality
and body weight [65]. There is also evidence that exercise
and maintaining a healthy body weight influence biomarkers
associated with progressive disease and overall survival (e.g.
insulin levels, inflammation) [61,62].
Despite this evidence, such interventions are not widely
disseminated into practice. Integrating heath behaviour
change interventions into standard survivorship care will
take a coordinated research agenda. Future research should
use a multi-level approach to elucidate the facilitators of
and barriers to behaviour change at the survivor, family, pro-
vider, healthcare system and public health levels. Mechanistic
research identifying the effects of health behaviour change
interventions on the integrated biological system within can-
cer survivors, rather than isolated pathways, will provide
needed information to engage physicians in prescribing these
interventions and in securing their reimbursement by insur-
ers. Research should determine the optimal types, doses
and timing of interventions needed for different groups of
cancer survivors, depending on survivors’ individual biology,
sociodemographic characteristics, outcome needs and psy-
chosocial circumstances, recognising that one size will notfit all. Targeted interventions aimed at specific groups, along
with tailoring of interventions to individuals’ needs and cir-
cumstances may increase uptake, utilisation and overall
impact. Research should also focus on determining optimal
methods to support survivors who need to make multiple
behaviour changes (e.g. improve diet, increase physical activ-
ity and stop smoking). Additionally, most research has
focused on helping survivors initiate healthy behaviour
changes; research is also needed to help survivors maintain
meaningful changes in health behaviour over time.
Most RCTs, to date, have focused onmore highly educated,
wealthier, Caucasian and younger female breast cancer survi-
vors. Future research should include more diverse survivor
populations. Studies are especially needed to understand
how to overcome barriers and promote health behaviour
changes in low-SES or minority communities, among men,
and among adults over the age of 65 with comorbidities. This
latter population is the largest segment of cancer survivors,
but is typically excluded from health behaviour change
research.
Many survivors report intentionally improving health
through diet, exercise or smoking cessation after cancer [66],
and over 50% of survivors voice an interest in pursuing healthy
behaviour change interventions [67]. There is an inherent bias
in current RCTs targeting behaviour change, as it is these
highly motivated survivors who tend to enrol in studies. How-
ever, there is an important subgroup of survivors who report
not contemplating or having no interest in making healthy
behaviour changes [67]. Future research should identify strat-
egies for engaging these survivors and motivating them to
undertake health behaviour changes. This includes research
addressing the underlying value of eating healthy and being
physically active, as well as considering how survivors think
about health behaviour change in the context of competing
values and priorities (e.g. reduced timewith family). Addition-
ally, linking behaviour change to outcomes survivors see as
important, such as physical and cognitive functionings, recur-
rence/survival and quality of life, may help them recognise the
value of behaviour change interventions.
Finally, behaviour change RCTs should be designed to fos-
ter dissemination and implementation in a variety of settings.
Data on costs, including intervention staff time, clinic time
and patient/family costs need to be collected as part of RCTs.
Trial designs should attempt to optimise post-intervention
sustainability by, for example, engaging stakeholders (e.g. sur-
vivors, healthcare providers, insurers, community partners)
from the beginning of the study and conducting RCTs in the
settings where later adoption is likely (e.g. community set-
tings). Clinic or other facility-based interventions should
build in components transitioning the intervention to the
home or community setting to facilitate sustainability and
maintenance of behaviour changes.
7. Work participation among cancer survivors
Research on employment and work-related issues has con-
vincingly shown high motivation among cancer survivors to
return to work after primary treatment has been completed.
Approximately two-thirds of cancer patients either continue
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Aside from the obvious financial benefits associated with
(return to) work [69], cancer survivors also experience work
as a means of maintaining their personal identity, a sense
of normalcy, social relationships, self-esteem, self-worth,
social roles, life satisfaction and quality of life [70–72]. How-
ever, the process of returning to work is a difficult one for
many survivors due to chronic physical, emotional and occu-
pational problems [73–76]. Cancer survivors are more likely to
be unemployed than their peers in the general population
[77], and they have an increased risk of early retirement [78].
Return to work after a cancer diagnosis is associated with
a number of sociodemographic and clinical factors. Younger,
male, well-educated survivors are more likely to resume their
working life. Thosewith early stage disease, who undergo less
invasive treatment and as a result are less fatigued, have
fewer symptoms and who are in better physical condition
are also more likely to be motivated to and to actually return
to work [68]. Additionally, work-related factors such as the
employers’ willingness to allow flexible working arrange-
ments, having supportive colleagues, being engaged in non-
manual work and having a higher salaried position contribute
to successful return to work.
In industrialised countries, it has been estimated that
approximately 42% of cancer patients are diagnosed at a
working age (between 15 and 64 years) [79]. A recent study
evaluated the costs of all cancers in a population-based cost
analysis including health-care costs, informal care costs and
productivity losses [80]. It was estimated that, in 2009, cancer
cost the European Union €126 billion; 60% of the economic
burden of cancer was in non-health-care areas, with almost
€43 billion in lost productivity due to early death and €9.5 bil-
lion due to lost working days.
These figures illustrate the importance of both epidemiol-
ogic and interventional research to better understand the fac-
tors that affect employment, work and work disability, and to
develop initiatives that create optimal opportunities for can-
cer survivors to return to work, if they so desire. Towards this
end, the Cancer and Work Network (CANWON) was estab-
lished in 2013. CANWON’s objectives include the assessment
of prognostic factors and work participation in cancer
patients, to identify indirect costs of cancer survivorship, to
gain significant knowledge about the role of the employer in
work participation and to develop innovative interventions
to enhance work participation of cancer patients [77].
Future research should consider the range of individual and
interpersonal factors, the short- and longer-term treatment
factors and the work environment and overall legal, organisa-
tional and financial factors that may affect employment and
return to work. Research should take into account different
perspectives on work participation in cancer survivorship,
including that of: (1) the cancer survivor; (2) the caregiver
and the family; (3) the employer and coworkers; (4) the health
care providers; and (5) the community or society, at large.
More research is particularly needed among those
survivors with a lower socioeconomic status, difficult working
conditions and occupational problems. Integrated multidisci-
plinary team approaches to medical and occupational
rehabilitation programmes are needed that address individual
and treatment-related factors, and that are tailored to theindividual’s work-related needs. Interventions are needed at
the workplace itself that involve employers. Finally, more
efforts should be invested in programmes aimed at long-term
cancer survivorswhere the focus is on sustaining work perfor-
mance and satisfaction after the initial return to work. To use
limited resources most effectively, screening procedures need
to be developed that identify those cancer survivors at high
risk for negative work outcomes.8. Evaluating the health-related quality of life
(HRQOL) of cancer survivors
The HRQOL of cancer survivors can be assessed with three
classes of self-report questionnaires or patient-reported out-
comes (PRO’s): (1) generic measures developed for use with
the widest possible range of health and clinical populations,
including patients with cancer; (2) cancer-specific measures;
and (3) cancer survivor-specific measures. The most well-
known and widely used generic HRQOL questionnaire inter-
nationally is the Short-Form 36-Item Health Survey or SF-36
[81]. The original 1.0 version has been translated and vali-
dated in a very large number of countries, including most
countries in Europe. There are also good general population
norms available for the original SF-36 in many countries,
although some are quite outdated [82]. The more recent, ver-
sion 2.0 of the SF-36 incorporates some minor but useful
changes in item wording, but most importantly it employs a
norm-based scoring procedure, using U.S. normative data
[83]. To date, the SF-36 version 2.0 has been normed in only
a limited number of countries outside of the U.S. For this rea-
son, many international researchers either continue to use
the original version or use the newer version, but with U.S.
norm-based scoring. Perhaps the most important limitation
of the SF-36 for use in cancer survivorship studies is that it
does not cover many of the HRQOL issues that are of specific
concern to cancer survivors (e.g. fear of disease recurrence,
return to work, financial problems, sexuality, etc.).
At the next level are cancer-specific HRQOL question-
naires, of which the two most widely used internationally
are those of the EORTC [84] and of the FACT group in the Uni-
ted States [85]. Both the EORTC and the FACT employ a mea-
surement system that includes a core questionnaire (the
QLQ-C30 and the FACT-G, respectively) intended for use with
all cancer patients, irrespective of diagnosis or treatment, and
condition-specific, supplemental questionnaires that address
HRQOL issues specific to particular patient populations (e.g.
breast, colon or lung cancer). Both the EORTC and FACT suites
of measures have been translated and validated in a wide
range of languages and countries, and there are some general
population normative data available for the core question-
naires. While both the EORTC and FACT measures can be
(and are) used in cancer survivorship studies, there is a need
for careful review of their content to ensure their relevance
and comprehensiveness of coverage, particularly for long-
term survivors. For example, some items addressing acute
symptoms such as emesis may no longer be relevant, while
other topics may not be covered adequately.
Finally, there are a number of questionnaires developed
specifically for use among cancer survivors. Muzzatti and
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questionnaires, and concluded that most have not yet under-
gone the requisite psychometric work to verify their reliability
and validity [86]. The two measures that were judged as most
promising are the revised version of the Impact of Cancer
questionnaire (IOCv2) [87] and the Quality of Life in Adult
Cancer Survivors (QLACS) questionnaire [88]. Both question-
naires have a relatively clear subscale structure, and have
been shown to be reliable and valid in a number of studies.
They have been used in some international studies, but still
require translation and validation in most European
countries.
Thus, although there is a range of HRQOL measures that
can be used in survivorship studies, there is clear need for
additional methodological research in this area. This
includes: (1) generating normative data for the SF-36v2 in a
wider range of European countries; (2) systematically assess-
ing the content of the EORTC and the FACT HRQOL measures
to ensure their suitability for use among cancer survivor pop-
ulations and, where necessary, revising or adapting them for
such use; and (3) translating and validating the most promis-
ing cancer survivor-specific questionnaires for use in a
broader range of European countries.
9. Research methodologies and use of cancer
registries
Despite the growing interest in health-related quality of life
(HRQOL) and other patient-reported outcomes (PROs) as indi-
cators of treatment efficacy in cancer clinical trials, it is not
yet customary to continue collecting such data for extended
periods of time after trial completion. Guidelines and stan-
dards for evaluating HRQOL in randomised clinical trials have
been published (CONSORT; Consolidated Standards of Report-
ing Clinical Trials) [89], but long-term follow-up of clinical
trial participants is expensive and labour-intensive. Research-
ers have had variable success in attempting to retrospectively
recruit survivors who participated in earlier clinical trials in
order to assess chronic or late effects of treatment [90,91].
Typical problems that arise with such a retrospective recruit-
ment approach are difficulty in locating patients, lack of insti-
tutional commitment, lack of patient interest and ethical
issues (not having an individual’s informed consent for
long-term follow-up) [90].
To date, most studies evaluating PRO’s among cancer sur-
vivors have employed a cross-sectional, observational design.
However, there are examples of successful prospective, obser-
vational cohort studies that have followed cancer survivors
over longer periods of time [92,93].
Cancer registries are increasingly being used to identify
and recruit cancer survivors into observational HRQOL stud-
ies. Because of the population-based nature of cancer regis-
tries, institutional referral bias can be avoided and better
external validity can be obtained. Another advantage is the
large number of survivors that can be included with a wide
geographic reach.
A recent review of cancer registries as a resource for
HRQOL research in cancer survivorship found that most stud-
ies included survivors of more common malignancies, suchas breast, colorectal and prostate cancer [94]. Surprisingly
few studies have focused on the HRQOL of survivors of less
common forms of cancer or of elderly cancer survivors. We
would recommend that future registry-based studies focus
specifically on these understudied subgroups of cancer
survivors.
The recently completed EUROCOURSE (‘Europe against
Cancer; Optimisation of the Use of Registries for Scientific
Excellence in Research’: www.eurocourse.org) project is an
example of how researchers from various countries (in this
case, France, Germany, Ireland, the Netherlands and the UK)
can exchange experiences and initiate cancer registry-based,
collaborative HRQOL research. Privacy regulations, difficulties
obtaining ethical approval and recruiting survivors and
obtaining (programmatic) funding are the most common
challenges facing cancer registries that wish to conduct
HRQOL survivorship studies. Individual countries also have
their own specific issues, and thus we recommend conduct-
ing local/national pilot projects that can help determine
how best to conduct long-term survivorship studies within
the context of specific registry laws and privacy regulations.
Additionally, sharing such information across countries could
facilitate the identification of practice variations, and ulti-
mately achieving (inter)national standards for survivorship
research [94].
To be able to interpret cancer survivors’ scores on HRQOL
and other PRO measures, it is useful to have normative data
from the general population. Such reference data allow us
to estimate the extent to which observed functional impair-
ment and symptom burden are associated with and can be
attributed to cancer and its treatment, rather than comorbid
conditions or simply to the ageing process. Normative data
for questionnaires that are often used in cancer survivorship
studies (e.g. the SF-36, the QLQ-C30) are available for a num-
ber of, but certainly not all European countries. Additionally,
normative data for such questionnaires can become dated,
and thus it is important to regularly update normative dat-
abases, preferably using a common protocol (e.g. for estab-
lishing the sampling frame and procedures, for data
collection) across countries. This will facilitate meaningful
international comparisons of cancer survivor experiences
[95].
10. Summary and conclusions
In this paper we have reviewed a number of key areas of psy-
chosocial research and practice in cancer survivorship. For
each of these areas, we have identified what we believe to
be important directions for future research. We are cognizant
of the fact that our review does address all potential psycho-
social issues relevant to cancer survivors. Separate papers in
this special issue of the European Journal of Cancer are devoted
to sexuality/fertility and to cognitive functioning in cancer
survivors. Other issues, such as social relationships, spiritual-
ity and positive growth opportunities, are clearly relevant, but
were beyond the scope of this paper.
We know that about one-third of cancer survivors suffer
from post-cancer pain syndrome, which can have a negative
and sustained impact on both physical and psychosocial
E J C S U P P L E M E N T S 1 2 ( 2 0 1 4 ) 5 4 –6 4 61functioning. Pain should not be viewed as an isolated symp-
tom, but rather in a cluster together with other symptoms
(e.g. anxiety, depression, fatigue, sleep disturbance). Studies
are needed on models of care that employ a multidisciplinary
approach to pain management, combining drugs and other
medical interventions with physical therapy, and psychoso-
cial interventions aimed at patient education and self-
management.
Cancer-related fatigue is an even more prevalent problem
among cancer survivors, and one that also requires a compre-
hensive, multifactorial, approach to treatment. Longitudinal
studies with long-term follow-up are needed to better under-
stand the risk factors associated with chronic fatigue follow-
ing cancer treatment. Future studies should investigate both
intensive interventions targeted at those with severe fatigue,
and lower intensity interventions for survivors with mild to
moderate fatigue complaints. The availability of brief and
diagnostically accurate screening questionnaires could facili-
tate triaging survivors into the most appropriate care
pathway.
Overall, about one-third of cancer patients experience
symptoms of psychological distress. The many controlled tri-
als investigating the efficacy of psychosocial interventions for
the treatment of distress have yielded inconsistent results.
This reflects, in large part, the variable methodological quality
of these trials. Future trials should investigate protocol-based
interventions, use rigorous research methods and adhere to
state-of-the art reporting standards. There is particular need
for tailored interventions that take into account the nature
and severity of distress and the cancer survivors’ background
characteristics, and that are cost-effective.
One approach to providing cost-effective psychosocial care
is the use of (guided) self-management strategies and eHealth
tools. Such interventions need to have a strong conceptual
basis, be evidence-based and target somatic and psychosocial
problems that are important to cancer survivors. Additionally,
effective implementation strategies need to be an integral
part of any self-management, blended care, or e-Health
initiative.
There is growing evidence that a healthy lifestyle reduces
the risk of morbidity and mortality after cancer, and that
many behavioural and lifestyle interventions (e.g. diet, exer-
cise) are both safe and effective. Yet, such interventions are
not widely available, and when available, not widely used.
Future research is needed to better understand the factors
that inhibit and facilitate the uptake of such programmes by
cancer survivors, health care providers and health care sys-
tems. More basic research is also needed to elucidate the
pathways and mechanisms through which health behaviour
changes affect health risks and health outcomes in the cancer
survivor population. At a practical level, research is needed to
help those who require multiple behaviour changes, to facili-
tate maintaining behaviour change once initiated and to
encourage behaviour change among those who are socioeco-
nomically disadvantaged.
Many cancer survivors want and/or need to continue
working during or to return to work as soon as possible after
ending primary treatment. This is in the interest of both the
cancer survivor and society at large. Future research is needed
to identify individual, interpersonal and structural factorsthat promote or impede return to work. Interventions tar-
geted at work resumption should engage both the worker
and the employer. There is a particular need for return-to-
work programmes for vulnerable, high-risk populations, such
as those with lower socioeconomic status and with difficult
work conditions.
Assessment is an important element of any effort to
improve the psychosocial health of cancer survivors. We
already have at our disposal a range of self-report measures
for assessing symptoms, functioning and well-being, some
of which have been developed specifically for use in cancer
survivor populations. Future research should focus on refin-
ing these measures, on making them available in a broader
range of cultures and languages, and on generating norma-
tive data for various measures to facilitate our understanding
of how cancer survivors feel and function in comparison to
their peers.
Finally, we would advocate greater use of cancer registries
to facilitate high quality, population-based investigations of
the quality of life of cancer survivors. While there are exam-
ples of successful use of registry data for such purposes, most
studies have focused on the more common cancer survivor
populations. Future efforts should be directed towards
patients with less common cancers, and at vulnerable popu-
lations of cancer survivors, including the elderly, underserved
ethnic minorities and the socioeconomically disadvantaged.
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